Blog - Visikol - Part 38

Using Multiplex Imaging and Digital Pathology for IO Therapeutics

Mike Johnson2019-10-02T19:32:57-05:00

Over the last few years, the development of immuno-oncology therapeutics has been on the rise with many leading pharmaceutical [...]

Mike Johnson2019-08-27T16:01:37-05:00

Visikol original spun out of Rutgers University and is now a leading contract research organization in the fields of [...]

Mike Johnson2019-08-27T15:48:55-05:00

This year, BMS will be hosting its 44th annual BMSIARC conference at the Crowne Plaza Princeton Conference Center from [...]

At Visikol, we are dedicated to not only providing our Clients with best-in-class drug discovery services but also continuing [...]

Mike Johnson2019-08-16T10:12:11-05:00

Breast cancer is one of the most commonly diagnosed cancers among American women, and while early detection and intervention [...]

Mike Johnson2019-08-13T10:11:16-05:00

Due to their relatively low cost, higher throughput and continually improving predictive capacity, researchers are increasingly turning to in [...]

The last few years have been very exciting for cell biology and drug discovery in general with the application [...]

Over the last few years, the Visikol portfolio of tissue clearing reagents have been used by over a thousand [...]

Mike Johnson2019-07-25T07:07:44-05:00Tags: immuno-oncology|

Visikol is heading to the Westin Waterfront in Boston for this year’s Immuno-Oncology Summit from August 5th-9st. Come visit [...]

Viability is a ubiquitous endpoint in cell-based assays. The results make a general claim about the current state of [...]